array(40) {
  [0]=>
  string(4) "9092"
  ["article_id"]=>
  string(4) "9092"
  [1]=>
  string(76) "Reduced Blood Lead Levels Linked to Lower Blood Pressure in American Indians"
  ["article_title"]=>
  string(76) "Reduced Blood Lead Levels Linked to Lower Blood Pressure in American Indians"
  [2]=>
  string(159) "&#nlReductions correlated with long-term cardiovascular health improvements in NIH-funded study.&#nl&#nlJanuary 11, 2024 -- Researchers have linked a decade-lo"
  ["short_description"]=>
  string(159) "&#nlReductions correlated with long-term cardiovascular health improvements in NIH-funded study.&#nl&#nlJanuary 11, 2024 -- Researchers have linked a decade-lo"
  [3]=>
  string(258) "&#nlReductions correlated with long-term cardiovascular health improvements in NIH-funded study.&#nl&#nlJanuary 11, 2024 -- Researchers have linked a decade-long decline in the blood lead levels of American Indian adults to long-term cardiovascular health..."
  ["description"]=>
  string(258) "&#nlReductions correlated with long-term cardiovascular health improvements in NIH-funded study.&#nl&#nlJanuary 11, 2024 -- Researchers have linked a decade-long decline in the blood lead levels of American Indian adults to long-term cardiovascular health..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(119) "https://www.drugs.com/clinical_trials/reduced-blood-lead-levels-linked-lower-blood-pressure-american-indians-21272.html"
  ["blog_url"]=>
  string(119) "https://www.drugs.com/clinical_trials/reduced-blood-lead-levels-linked-lower-blood-pressure-american-indians-21272.html"
  [15]=>
  string(19) "2024-01-12 03:01:31"
  ["add_date"]=>
  string(19) "2024-01-12 03:01:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9235"
  ["article_id"]=>
  string(4) "9235"
  [1]=>
  string(73) "Geisinger gets USDA rural development grant for inpatient virtual nursing"
  ["article_title"]=>
  string(73) "Geisinger gets USDA rural development grant for inpatient virtual nursing"
  [2]=>
  string(150) "Nearly $950,000 in new funding will help the Pennsylvania health system expand the 24/7 virtual care center it launched this past year, with new techn"
  ["short_description"]=>
  string(150) "Nearly $950,000 in new funding will help the Pennsylvania health system expand the 24/7 virtual care center it launched this past year, with new techn"
  [3]=>
  string(238) "Nearly $950,000 in new funding will help the Pennsylvania health system expand the 24/7 virtual care center it launched this past year, with new technologies for Geisinger Medical Center and Geisinger Shamokin Area Community Hospital.&#nl"
  ["description"]=>
  string(238) "Nearly $950,000 in new funding will help the Pennsylvania health system expand the 24/7 virtual care center it launched this past year, with new technologies for Geisinger Medical Center and Geisinger Shamokin Area Community Hospital.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(107) "https://www.healthcareitnews.com/news/geisinger-gets-usda-rural-development-grant-inpatient-virtual-nursing"
  ["blog_url"]=>
  string(107) "https://www.healthcareitnews.com/news/geisinger-gets-usda-rural-development-grant-inpatient-virtual-nursing"
  [15]=>
  string(19) "2024-01-12 00:23:32"
  ["add_date"]=>
  string(19) "2024-01-12 00:23:32"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9236"
  ["article_id"]=>
  string(4) "9236"
  [1]=>
  string(76) "ONC should tailor info blocking disincentives to provider types, groups say "
  ["article_title"]=>
  string(76) "ONC should tailor info blocking disincentives to provider types, groups say "
  [2]=>
  string(150) "EHRA, HIMSS and others cite regulatory variability and redundancy, as well as costs, as roadblocks to interoperable health information exchange, while"
  ["short_description"]=>
  string(150) "EHRA, HIMSS and others cite regulatory variability and redundancy, as well as costs, as roadblocks to interoperable health information exchange, while"
  [3]=>
  string(209) "EHRA, HIMSS and others cite regulatory variability and redundancy, as well as costs, as roadblocks to interoperable health information exchange, while ACR stresses investigatory protections for physicians.&#nl"
  ["description"]=>
  string(209) "EHRA, HIMSS and others cite regulatory variability and redundancy, as well as costs, as roadblocks to interoperable health information exchange, while ACR stresses investigatory protections for physicians.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(109) "https://www.healthcareitnews.com/news/onc-should-tailor-info-blocking-disincentives-provider-types-groups-say"
  ["blog_url"]=>
  string(109) "https://www.healthcareitnews.com/news/onc-should-tailor-info-blocking-disincentives-provider-types-groups-say"
  [15]=>
  string(19) "2024-01-11 23:58:19"
  ["add_date"]=>
  string(19) "2024-01-11 23:58:19"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9146"
  ["article_id"]=>
  string(4) "9146"
  [1]=>
  string(149) "Vibra Healthcare and Monument Health Collaborate to Open the Rehabilitation and Critical Care Hospital of the Black Hills in Rapid City, South Dakota"
  ["article_title"]=>
  string(149) "Vibra Healthcare and Monument Health Collaborate to Open the Rehabilitation and Critical Care Hospital of the Black Hills in Rapid City, South Dakota"
  [2]=>
  string(149) "Vibra Healthcare and Monument Health Collaborate to Open the Rehabilitation and Critical Care Hospital of the Black Hills in Rapid City, South Dakota"
  ["short_description"]=>
  string(149) "Vibra Healthcare and Monument Health Collaborate to Open the Rehabilitation and Critical Care Hospital of the Black Hills in Rapid City, South Dakota"
  [3]=>
  string(149) "Vibra Healthcare and Monument Health Collaborate to Open the Rehabilitation and Critical Care Hospital of the Black Hills in Rapid City, South Dakota"
  ["description"]=>
  string(149) "Vibra Healthcare and Monument Health Collaborate to Open the Rehabilitation and Critical Care Hospital of the Black Hills in Rapid City, South Dakota"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(220) "https://www.globenewswire.com/news-release/2024/01/11/2808113/0/en/Vibra-Healthcare-and-Monument-Health-Collaborate-to-Open-the-Rehabilitation-and-Critical-Care-Hospital-of-the-Black-Hills-in-Rapid-City-South-Dakota.html"
  ["blog_url"]=>
  string(220) "https://www.globenewswire.com/news-release/2024/01/11/2808113/0/en/Vibra-Healthcare-and-Monument-Health-Collaborate-to-Open-the-Rehabilitation-and-Critical-Care-Hospital-of-the-Black-Hills-in-Rapid-City-South-Dakota.html"
  [15]=>
  string(19) "2024-01-11 23:38:00"
  ["add_date"]=>
  string(19) "2024-01-11 23:38:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9237"
  ["article_id"]=>
  string(4) "9237"
  [1]=>
  string(43) "Effects of the EU AI Act Visible After 2026"
  ["article_title"]=>
  string(43) "Effects of the EU AI Act Visible After 2026"
  [2]=>
  string(150) "2023 was the year marked by AI. With the rise of general-purpose large language models ChatGPT, Claude and Bard, AI has become tangible and accessible"
  ["short_description"]=>
  string(150) "2023 was the year marked by AI. With the rise of general-purpose large language models ChatGPT, Claude and Bard, AI has become tangible and accessible"
  [3]=>
  string(320) "2023 was the year marked by AI. With the rise of general-purpose large language models ChatGPT, Claude and Bard, AI has become tangible and accessible for millions of people. There was no shortage of excitement, but also appeals for regulation of this powerful technology. &#nlState of AI Regulation in Healthcare&#nl"
  ["description"]=>
  string(320) "2023 was the year marked by AI. With the rise of general-purpose large language models ChatGPT, Claude and Bard, AI has become tangible and accessible for millions of people. There was no shortage of excitement, but also appeals for regulation of this powerful technology. &#nlState of AI Regulation in Healthcare&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(79) "https://www.healthcareitnews.com/news/emea/effects-eu-ai-act-visible-after-2026"
  ["blog_url"]=>
  string(79) "https://www.healthcareitnews.com/news/emea/effects-eu-ai-act-visible-after-2026"
  [15]=>
  string(19) "2024-01-11 23:02:38"
  ["add_date"]=>
  string(19) "2024-01-11 23:02:38"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9043"
  ["article_id"]=>
  string(4) "9043"
  [1]=>
  string(180) "Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions"
  ["article_title"]=>
  string(180) "Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions"
  [2]=>
  string(150) "Audience: Patient, Health Professional, Endocrinology, Pharmacy ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients"
  ["short_description"]=>
  string(150) "Audience: Patient, Health Professional, Endocrinology, Pharmacy ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients"
  [3]=>
  string(252) "Audience: Patient, Health Professional, Endocrinology, Pharmacy ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see..."
  ["description"]=>
  string(252) "Audience: Patient, Health Professional, Endocrinology, Pharmacy ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(134) "https://www.drugs.com/fda/safety-communication-certain-type-medicines-approved-type-2-diabetes-obesity-update-fda-s-ongoing-14649.html"
  ["blog_url"]=>
  string(134) "https://www.drugs.com/fda/safety-communication-certain-type-medicines-approved-type-2-diabetes-obesity-update-fda-s-ongoing-14649.html"
  [15]=>
  string(19) "2024-01-11 21:57:00"
  ["add_date"]=>
  string(19) "2024-01-11 21:57:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9310"
  ["article_id"]=>
  string(4) "9310"
  [1]=>
  string(72) "Amgen has potential to compete with established leaders in obesity drugs"
  ["article_title"]=>
  string(72) "Amgen has potential to compete with established leaders in obesity drugs"
  [2]=>
  string(133) "On January 8, Amgen presented at JP Morganâs 42nd Annual Healthcare Conference 2024 (JPM24), highlighting its pillars of business."
  ["short_description"]=>
  string(133) "On January 8, Amgen presented at JP Morganâs 42nd Annual Healthcare Conference 2024 (JPM24), highlighting its pillars of business."
  [3]=>
  string(133) "On January 8, Amgen presented at JP Morganâs 42nd Annual Healthcare Conference 2024 (JPM24), highlighting its pillars of business."
  ["description"]=>
  string(133) "On January 8, Amgen presented at JP Morganâs 42nd Annual Healthcare Conference 2024 (JPM24), highlighting its pillars of business."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(178) "https://www.biopharma-reporter.com/Article/2024/01/11/amgen-has-potential-to-compete-with-established-leaders-in-obesity-drugs?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(178) "https://www.biopharma-reporter.com/Article/2024/01/11/amgen-has-potential-to-compete-with-established-leaders-in-obesity-drugs?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-11 21:21:00"
  ["add_date"]=>
  string(19) "2024-01-11 21:21:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:36"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9311"
  ["article_id"]=>
  string(4) "9311"
  [1]=>
  string(102) "AbbVie’s Produodopa holds potential to become first-choice pump for advanced Parkinson’s"
  ["article_title"]=>
  string(102) "AbbVie’s Produodopa holds potential to become first-choice pump for advanced Parkinson’s"
  [2]=>
  string(152) "Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinsonâs disease (PD) in the E"
  ["short_description"]=>
  string(152) "Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinsonâs disease (PD) in the E"
  [3]=>
  string(237) "Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinsonâs disease (PD) in the European Union (EU), Christine Wong, neurology analyst at GlobalData, offers her view:"
  ["description"]=>
  string(237) "Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinsonâs disease (PD) in the European Union (EU), Christine Wong, neurology analyst at GlobalData, offers her view:"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(194) "https://www.biopharma-reporter.com/Article/2024/01/11/abbvie-s-produodopa-holds-potential-to-become-first-choice-pump-for-advanced-parkinson-s?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(194) "https://www.biopharma-reporter.com/Article/2024/01/11/abbvie-s-produodopa-holds-potential-to-become-first-choice-pump-for-advanced-parkinson-s?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-11 21:19:00"
  ["add_date"]=>
  string(19) "2024-01-11 21:19:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:36"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9312"
  ["article_id"]=>
  string(4) "9312"
  [1]=>
  string(112) "Ariceum Therapeutics files for UK Clinical Trial Authorisation to test PARP inhibitor for glioblastoma patients "
  ["article_title"]=>
  string(112) "Ariceum Therapeutics files for UK Clinical Trial Authorisation to test PARP inhibitor for glioblastoma patients "
  [2]=>
  string(150) "Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has "
  ["short_description"]=>
  string(150) "Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has "
  [3]=>
  string(372) "Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has submitted an application with the UKâs Medicines and Healthcare products Regulatory Agency (MHRA) to undertake a phase 1 trial of I-ATT001, its Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma."
  ["description"]=>
  string(372) "Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has submitted an application with the UKâs Medicines and Healthcare products Regulatory Agency (MHRA) to undertake a phase 1 trial of I-ATT001, its Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(194) "https://www.biopharma-reporter.com/Article/2024/01/11/Ariceum-Therapeutics-files-for-UK-Clinical-Trial-Authorisation-to-glioblastoma-treatment?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(194) "https://www.biopharma-reporter.com/Article/2024/01/11/Ariceum-Therapeutics-files-for-UK-Clinical-Trial-Authorisation-to-glioblastoma-treatment?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-11 21:19:00"
  ["add_date"]=>
  string(19) "2024-01-11 21:19:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:36"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:36"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9211"
  ["article_id"]=>
  string(4) "9211"
  [1]=>
  string(80) "Challenges in data management - from breaking data silos to data democratization"
  ["article_title"]=>
  string(80) "Challenges in data management - from breaking data silos to data democratization"
  [2]=>
  string(150) "WNS supports the research and brand teams of more than 30 life sciences companies. The company believes its comprehensive pharma market research capab"
  ["short_description"]=>
  string(150) "WNS supports the research and brand teams of more than 30 life sciences companies. The company believes its comprehensive pharma market research capab"
  [3]=>
  string(225) "WNS supports the research and brand teams of more than 30 life sciences companies. The company believes its comprehensive pharma market research capabilities help clients in assimilating information from various data sources."
  ["description"]=>
  string(225) "WNS supports the research and brand teams of more than 30 life sciences companies. The company believes its comprehensive pharma market research capabilities help clients in assimilating information from various data sources."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(169) "https://www.outsourcing-pharma.com/Article/2024/01/11/Interview-WNS-on-the-trials-and-tribulations-of-data-management?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(169) "https://www.outsourcing-pharma.com/Article/2024/01/11/Interview-WNS-on-the-trials-and-tribulations-of-data-management?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2024-01-11 17:58:00"
  ["add_date"]=>
  string(19) "2024-01-11 17:58:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:49"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9193"
  ["article_id"]=>
  string(4) "9193"
  [1]=>
  string(37) "Optimal introduces SciYbotic TT range"
  ["article_title"]=>
  string(37) "Optimal introduces SciYbotic TT range"
  [2]=>
  string(150) "The TT range from Optimal is part of the broader SciYbotic Quality Test Machines series of at-line solutions that enable the digitalisation of pharmac"
  ["short_description"]=>
  string(150) "The TT range from Optimal is part of the broader SciYbotic Quality Test Machines series of at-line solutions that enable the digitalisation of pharmac"
  [3]=>
  string(216) "The TT range from Optimal is part of the broader SciYbotic Quality Test Machines series of at-line solutions that enable the digitalisation of pharmaceutical manufacturing from the lab to commercial-scale production."
  ["description"]=>
  string(216) "The TT range from Optimal is part of the broader SciYbotic Quality Test Machines series of at-line solutions that enable the digitalisation of pharmaceutical manufacturing from the lab to commercial-scale production."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(108) "https://www.medicalplasticsnews.com/news/latest-medical-plastics-news/optimal-introduces-sciybotic-tt-range/"
  ["blog_url"]=>
  string(108) "https://www.medicalplasticsnews.com/news/latest-medical-plastics-news/optimal-introduces-sciybotic-tt-range/"
  [15]=>
  string(19) "2024-01-11 17:30:00"
  ["add_date"]=>
  string(19) "2024-01-11 17:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:42"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:42"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9147"
  ["article_id"]=>
  string(4) "9147"
  [1]=>
  string(171) "Press release Biocartis Group NV: Disclosure of transparency notification  (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)"
  ["article_title"]=>
  string(171) "Press release Biocartis Group NV: Disclosure of transparency notification  (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)"
  [2]=>
  string(45) "BIOCARTIS GROUP NV (Euronext Brussels: BCART)"
  ["short_description"]=>
  string(45) "BIOCARTIS GROUP NV (Euronext Brussels: BCART)"
  [3]=>
  string(73) "
BIOCARTIS GROUP NV (Euronext Brussels: BCART)
"
  ["description"]=>
  string(73) "
BIOCARTIS GROUP NV (Euronext Brussels: BCART)
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(237) "https://www.globenewswire.com/news-release/2024/01/10/2807541/0/en/Press-release-Biocartis-Group-NV-Disclosure-of-transparency-notification-Article-14-first-paragraph-of-the-Act-of-2-May-2007-on-the-disclosure-of-large-shareholdings.html"
  ["blog_url"]=>
  string(237) "https://www.globenewswire.com/news-release/2024/01/10/2807541/0/en/Press-release-Biocartis-Group-NV-Disclosure-of-transparency-notification-Article-14-first-paragraph-of-the-Act-of-2-May-2007-on-the-disclosure-of-large-shareholdings.html"
  [15]=>
  string(19) "2024-01-11 06:00:00"
  ["add_date"]=>
  string(19) "2024-01-11 06:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}